Brokerages Set Phreesia, Inc. (NYSE:PHR) Price Target at $29.76

Shares of Phreesia, Inc. (NYSE:PHR) have earned an average recommendation of “Moderate Buy” from the nineteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $29.7647.

A number of equities research analysts recently weighed in on PHR shares. Canaccord Genuity Group lowered their target price on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, December 9th. BMO Capital Markets began coverage on Phreesia in a research note on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective for the company. DA Davidson cut their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Truist Financial set a $24.00 price target on Phreesia in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded Phreesia from a “buy” rating to a “strong-buy” rating in a research note on Saturday.

Insider Activity at Phreesia

In other Phreesia news, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the transaction, the insider owned 231,723 shares of the company’s stock, valued at $3,941,608.23. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 6,585 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the transaction, the general counsel directly owned 174,762 shares of the company’s stock, valued at approximately $2,972,701.62. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,766 shares of company stock valued at $1,013,817 over the last three months. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. UBS Group AG increased its position in shares of Phreesia by 8.3% during the 4th quarter. UBS Group AG now owns 214,987 shares of the company’s stock valued at $3,638,000 after purchasing an additional 16,529 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Phreesia by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock worth $97,194,000 after buying an additional 39,540 shares during the last quarter. Asset Management One Co. Ltd. grew its position in Phreesia by 244.4% during the fourth quarter. Asset Management One Co. Ltd. now owns 6,578 shares of the company’s stock valued at $112,000 after buying an additional 4,668 shares during the period. CWM LLC increased its holdings in Phreesia by 106.0% during the fourth quarter. CWM LLC now owns 6,888 shares of the company’s stock worth $117,000 after buying an additional 3,545 shares during the last quarter. Finally, KBC Group NV raised its position in Phreesia by 83.4% in the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after acquiring an additional 1,568 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Price Performance

Shares of PHR opened at $13.41 on Monday. The business’s fifty day moving average is $17.18 and its 200 day moving average is $22.43. Phreesia has a 12-month low of $13.40 and a 12-month high of $32.76. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The stock has a market cap of $808.49 million, a P/E ratio of -134.09 and a beta of 0.61.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business had revenue of $120.33 million during the quarter, compared to analyst estimates of $119.98 million. During the same quarter in the previous year, the business posted ($0.25) EPS. Phreesia’s quarterly revenue was up 12.7% on a year-over-year basis. Sell-side analysts anticipate that Phreesia will post -1.1 earnings per share for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.